Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬
的慢性丙肝（CHC）患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬的慢性丙肝（CHC）患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外，胰岛素抵抗和糖尿
是慢性丙型肝炎（CHC）中纤维
以及对抗毒治疗无应答的危因素。
声明：以上例句、词性分类均由互联网资源自动生成，部分未经过人工审核，其表达内容亦不代表本软件的观点；若发现问题，欢迎向我们指正。
